NEW YORK (GenomeWeb News) – Gentel Biosciences and Eprogen today said that they will collaborate on making whole proteome microarrays for identifying new autoantibody biomarkers.

Eprogen's ProteoSep protein fractionation technology enables whole proteome microarrays to be fabricated from individual cell lines or tissue samples, such as tumor biopsies. The firms will combine that technology with Gentel's protein microarray surface chemistries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.